Who are Eszopiclone 3 mg- Non-elderly's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zulresso, Onfi, Lusedra, Campral, Sonata, Suprane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eszopiclone-3-mg-non-elderly.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Eszopiclone 3 mg- Non-elderly — Competitive Intelligence Brief

Eszopiclone 3 mg- Non-elderly (Eszopiclone 3 mg- Non-elderly) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonbenzodiazepine hypnotic (Z-drug). Area: Neurology / Sleep Medicine.

phase 3 Nonbenzodiazepine hypnotic (Z-drug) GABA-A receptor Neurology / Sleep Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Eszopiclone 3 mg- Non-elderly (Eszopiclone 3 mg- Non-elderly) — Eisai Co., Ltd.. Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eszopiclone 3 mg- Non-elderly TARGET	Eszopiclone 3 mg- Non-elderly	Eisai Co., Ltd.	phase 3	Nonbenzodiazepine hypnotic (Z-drug)	GABA-A receptor
Zulresso	BREXANOLONE	Sage Therap	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2	2019-01-01
Onfi	CLOBAZAM	Lundbeck Pharms Llc	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	2011-01-01
Lusedra	FOSPROPOFOL		marketed	fospropofol	GABA-A receptor	2008-01-01
Campral	ACAMPROSATE	Allergan/AbbVie	marketed	acamprosate	GABA-A receptor alpha-1/beta-3/gamma-2	2004-01-01
Sonata	ZALEPLON	Pfizer	marketed	gamma-Aminobutyric Acid A Receptor Agonist [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	1999-01-01
Suprane	DESFLURANE	Baxter	marketed	General Anesthetic [EPC]	GABA-A receptor; anion channel	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2039-09-05 — Onfi · 12403090 · Formulation · US
2039-09-05 — Onfi · 12290597 · Formulation · US
2040-01-31 — Onfi · 11541002 · Formulation · US

Sponsor landscape (Nonbenzodiazepine hypnotic (Z-drug) class)

Eisai Co., Ltd. · 3 drugs in this class
Sumitomo Pharma America, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eszopiclone 3 mg- Non-elderly — Competitive Intelligence Brief. https://druglandscape.com/ci/eszopiclone-3-mg-non-elderly. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab